Status:
UNKNOWN
Oral Administration of Tranexamic Acid in Anterior Cruciate Ligament Surgery Reduce Postoperative Haemarthrosis
Lead Sponsor:
University of Liege
Conditions:
Hemorrhage Postoperative
Anterior Cruciate Ligament Rupture
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
To find superiority relationship between oral and intravenous administration of tranexamic acid on peroperative and postoperative blood loss, haemarthrosis prevalence and improvement functional progno...
Detailed Description
Tranexamic acid is an anti-fibrinolytic drug, recommended in total hip arthroplasty to reduce peroperative and postoperative hemorrhagic complications. The original character of our study lies in the ...
Eligibility Criteria
Inclusion
- Primary arthroscopic surgery for anterior cruciate ligament reconstruction
Exclusion
- Renal failure with serum creatinine level higher than 1,40 mg/dL
- Thromboembolic events in last 12 months before surgery
- Pregnancy
- Congenital or acquired coagulation diseases
- History of gastric surgery that could lead to malabsorption
- Diabetic gastro-paresis
Key Trial Info
Start Date :
July 6 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2023
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT04855877
Start Date
July 6 2021
End Date
July 1 2023
Last Update
July 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Liège
Liège, Belgium, 4000